Olmetrack CT 6.25 Tablet
Manufacturer
USV Ltd
Salt Composition
Olmesartan Medoxomil (20mg) + Chlorthalidone (6.25mg)
Key Information
Short Description
Olmetrack CT 6.25 Tablet is a combination of two medicines that helps to control high blood pressure in different ways.
Dosage Form
Tablet
Introduction
Olmetrack CT 6.25 Tablet is a combination of two medicines that helps to control high blood pressure in different ways. If high blood pressure is not treated, it can lead to heart attacks, strokes, and kidney failure.
Directions for Use
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush, or break it. Olmetrack CT 6.25 Tablet may be taken with or without food, but it is better to take it at a fixed time.
Safety Information
Side Effects
No common side effects listed.
Alcohol Warning
Olmetrack CT 6.25 Tablet may cause excessive drowsiness with alcohol.
Breastfeeding Warning
Olmetrack CT 6.25 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Pregnancy Warning
Olmetrack CT 6.25 Tablet is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
How it works
Olmetrack CT 6.25 Tablet is a combination of two medicines:
Quick Tips
You have been prescribed Olmetrack CT 6.25 Tablet for the treatment of high blood pressure. It can be taken with or without food. Olmetrack CT 6.25 Tablet may cause dehydration. Drink plenty of fluids and inform your doctor if you develop extreme thirst, very dry mouth, or muscle weakness. It may cause dizziness. Get up slowly when rising from a sitting or lying position. Use of Olmetrack CT 6.25 Tablet during pregnancy or breastfeeding is unsafe.
Related Medicines
Olsar CH 20/6.25 Tablet
Olmesar-CH 20/6.25 Tablet
Zione O 20mg/6.25mg Tablet
CTD-O 6.25/20 Tablet
Omen CT 20mg/6.25mg Tablet
Ibolme CT LD 20mg/6.25mg Tablet
Biolsar 20 Tablet
Olmeg CH 20mg/6.25mg Tablet
Winbp CT 20/6.25 Tablet
Frequently asked questions
How long does it take for Olmetrack CT 6.25 Tablet to work?
You may notice a decrease in your blood pressure effectively within 2 weeks of starting Olmetrack CT 6.25 Tablet. However, it may take about 8 weeks to see the full benefits of this medicine. Talk to your doctor if you have any concerns regarding Olmetrack CT 6.25 Tablet but do not stop taking it without consulting the doctor.
At what time of the day should I take Olmetrack CT 6.25 Tablet?
Your doctor may suggest to take your first dose before bedtime, considering that this medicine can make you feel dizzy. After the very first dose you can take Olmetrack CT 6.25 Tablet at any time of the day. It is important to take this medicine at the same time every day. If not sure, contact your doctor.
Can I feel dizzy after taking Olmetrack CT 6.25 Tablet?
Yes, the use of Olmetrack CT 6.25 Tablet can make you feel dizzy. This may occur when you suddenly get up from a lying or sitting position. To lower the chance of feeling dizzy or passing out, rise slowly if you have been sitting or lying down.
What are the other lifestyle changes I should make while using Olmetrack CT 6.25 Tablet?
Lifestyle changes play a major role in keeping you healthy if you are taking Olmetrack CT 6.25 Tablet. Avoid taking excess salt in your diet and find ways to reduce or manage stress in your life. Practice yoga or meditation or take up a hobby. Ensure that you have a sound sleep every night as this also helps to reduce stress levels and helps to keep your blood pressure normal. Stop smoking and alcohol consumption as this helps in lowering your blood pressure and preventing heart problems. Exercise regularly and take a balanced diet that includes whole grains, fresh fruits, vegetables and fat-free products. Consult your doctor if you need any further guidance to get the maximum benefit of Olmetrack CT 6.25 Tablet and to keep yourself healthy.
Can Olmetrack CT 6.25 Tablet cause weight gain?
No, Olmetrack CT 6.25 Tablet does not cause weight gain. However, in very rare cases, chronic diarrhea with substantial weight loss may occur. If a patient develops diarrhea while taking Olmetrack CT 6.25 Tablet and no other cause of diarrhea can be deduced, the doctor may suggest discontinuation of the medicine and recommend another medicine.
What are the serious side effects of Olmetrack CT 6.25 Tablet?
The serious side effects of Olmetrack CT 6.25 Tablet include skin rash or itchiness, painful joints, fast heart beat, shortness of breath or tightness in the chest. Serious side effects may also include aching, tender or weak muscles not caused by exercise and swelling of the hands, feet or ankles. Olmetrack CT 6.25 Tablet may also cause symptoms that may indicate high potassium levels in the blood, such as nausea, diarrhea, muscle weakness and change in heart rhythm. If you experience any of these symptoms, call your doctor immediately.
Can I take Olmetrack CT 6.25 Tablet before surgery?
Your doctor may advise you to stop taking Olmetrack CT 6.25 Tablet 24 hours before surgery. This is because Olmetrack CT 6.25 Tablet can further reduce your blood pressure when used with anesthetics, so inform your doctor that you are taking Olmetrack CT 6.25 Tablet if you will be given general anesthetics (medicines that put you to sleep) or are scheduled to have any surgery.
Is it safe to take Olmetrack CT 6.25 Tablet long term?
You may have to take Olmetrack CT 6.25 Tablet life long. Olmetrack CT 6.25 Tablet controls high blood pressure but does not cure it. Do not stop taking it even if your blood pressure is well controlled. Olmetrack CT 6.25 Tablet is generally considered safe to be taken for a long term. In some cases, long-term use may adversely affect the kidneys and the kidneys may not function as they should. Therefore, your doctor may prescribe regular blood tests to check urea, creatinine and potassium levels to keep a track of your kidney functions.
